Oleg Akilov
0000-0003-1339-5710
Medical Center, University of Pittsburgh
8 papers found
Refreshing results…
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data
Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1
Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index ( PROCLIPI ) study
Targeting CD47 in Sézary syndrome with SIRPαFc
Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome
Computer-aided classification of melanocytic lesions using dermoscopic images
Missing publications? Search for publications with a matching author name.